Recombinant human erythropoietin therapy has beneficial cardio-renal effects on moderate stages of chronic renal failure in the rat

• Type: Article in International Conference Proceedings Book
• Date: 2009

Authors

Garrido, P (Author) Other; Reis, F (Author) Other; Teixeira Lemos, E (Author) Other; Costa, E (Author) FFUP; Parada, B (Author) Other; Piloto, N (Author) Other; Sereno, J (Author) Other; Teixeira, A (Author) Other; Pinto, R (Author) Other; Figueiredo, A (Author) Other; Alves, R (Author) Other; Rocha Pereira, P (Author) Other; Belo, L (Author) FFUP; Santos Silva, A (Author) FFUP; Teixeira, F (Author) Other

Conference proceedings International

Title: 9TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS - EACPT

Pages: 177-180

9th Congress of the European-Association-for-Clinical-Pharmacology-and-Therapeutics (EACPT)

Edinburgh, SCOTLAND, JUL 12-15, 2009

Indexing

ISI Web of Knowledge - 0 Citations

Scientific classification

FOS: Medical and Health sciences > Basic medicine

Other information

Authenticus ID: P-003-T0T

Abstract (EN): This study aimed to assess the cardio-renal effects of rhEPO therapy on an animal model of moderate chronic renal failure (CRF). Four groups (n=7) of male rat were evaluated during a 12-week follow up period: control: rhEPO: 50 IU/Kg/wk. CRF: two stage 3/4 nephrectomy. CRF+ rhEPO (start after the 3rd wk of surgery). Renal function, haematology and serum inflammation and redox status were assessed. rhEPO treatment was able to partially attenuate renal function markers, totally correct anaemia, also showing a proliferative and antioxidant action, due to increased serum TGF-beta 1 and decreased 3-NT. In conclusion, rhEPO therapy might be recommended in moderate CRF stages in order to efficiently correct not only the underlying anaemia but also the deleterious cardio-renal effects, due to a proliferative and antioxidant renoprotective action.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 4